



Contact: Ralph Barry, Chief Business Officer
Aegis Therapeutics LLC
1-858-618-1400 Ext. 102
Email: rbarry@aegisthera.com

Aegis Therapeutics Invited to Present Intravail™ Drug Delivery Technology and Participate in Panel Session at SRI's "Peptides and Therapeutic Proteins Conference"

SAN DIEGO, CA August 15, 2005/BusinessWire/-- Aegis Therapeutics, a leader in intranasal and transmucosal delivery of peptide, protein, and non-protein macromolecular drugs, today announced that Edward T. Maggio, Ph.D., President and Chief Executive Officer, will present an overview of nasal delivery of peptides and small proteins, including the application of Aegis' Intravail™ non-invasive drug technology and will also participate in a panel entitled, "Difficult to Deliver Peptides and Proteins" at the Strategic Research Institute's conference entitled, "Peptides and Therapeutic Proteins: New Opportunities for Macromolecule Development, Delivery, and Commercialization" . The conference will take place on November 17-18, 2005 at the Hilton Philadelphia City Avenue - Philadelphia, PA.

Maggio commented: "Recent industry market research reports indicate that nearly 700 peptide drugs are currently in clinical and preclinical development. There is also rapidly growing interest in 'biogenerics' in the US, EU and Asia, making this a particularly timely conference for pharmaceutical executives seeking to offer effective new and non-invasive therapeutics."

Information about the conference may be obtained from the SRI website at: <http://www.srinstitute.com/>.

About Aegis Therapeutics

Aegis Therapeutics LLC is a specialty pharmaceutical company commercializing its patented Intravail™ drug delivery technology that enables the non-invasive delivery of a broad range of protein, peptide and non-peptide macromolecular therapeutics that can currently only be administered by injection. Aegis' Intravail™ absorption enhancement agents are mild and non-irritating to mucosal membranes. They provide exceptionally high and unmatched bioavailability performance, comparable in efficiency to subcutaneous injection, via the intranasal and other mucosal membrane administration routes. Intravail™ also provides for rapid drug absorption and onset of action, controlled transient permeation of the nasal mucosal barrier, avoidance of gastric hydrolysis and "first pass effect" elimination by the liver, greater patient convenience and compliance, elimination of needle-stick injuries and associated transmission of blood borne pathogens, compatibility with current nasal delivery devices, and ease of formulation, scale-up, and production. For more information about Aegis, please visit the Aegis website at: <http://www.aegisthera.com>.

###